The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. (Q45901690)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 December 2012

Language	Label	Description	Also known as
English	The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.	scientific article published on 15 December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

Claudia Durán-Aniotz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Diego Francisco Catalán

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Lorena Salazar

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cristián Pereda

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cristián Falcón

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Fabián Tempio

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Raquel Aguilera

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Rodrigo González

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Claudio Pérez

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Andrés Tittarelli

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Bruno Nervi

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Milton Larrondo

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Flavio Salazar-Onfray

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mercedes N López

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

15 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

62

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

761-772

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

https://scigraph.springernature.com/pub.10.1007/s00262-012-1377-3

0 references

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Immunotherapy for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The first 1000 dendritic cell vaccinees.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dendritic cells: immunobiology and cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Assessing oncologic benefit in clinical trials of immunotherapy agents

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Cancer immunology--analysis of host and tumor factors for personalized medicine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Importance of CD4(+) T helper cell responses in tumor immunity.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Tumor-specific Th17-polarized cells eradicate large established melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

T helper 17 cells promote cytotoxic T cell activation in tumor immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

'Yin-Yang' functions of transforming growth factor-beta and T regulatory cells in immune regulation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The polarization of immune cells in the tumour environment by TGFbeta

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Deciphering the role of Th17 cells in human disease

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

The roles of IFN gamma in protection against tumor development and cancer immunoediting

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Pretreatment frequency of circulating IL-17+CD4+T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1377-3

21 January 2018

Identifiers

10.1007/S00262-012-1377-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23242374%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45901690&oldid=1242740365"